Skip to main content
Erschienen in: World Journal of Urology 1/2004

01.04.2004 | Free Paper

Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis

verfasst von: Katie Forbes, Karin Gillette, Laura A. Kelley, Inder Sehgal

Erschienen in: World Journal of Urology | Ausgabe 1/2004

Einloggen, um Zugang zu erhalten

Abstract

To understand alterations to the urokinase system that may occur in progressively metastatic prostate cancer cells, we assessed urokinase plasminogen activator receptor (uPAR) expression, in vitro motility towards vitronectin, urokinase plasminogen activator (uPA)-induced growth and growth factor regulation of uPAR expression in three cell lines—PC-3 and two derivatives from secondary metastases, PC-3M and PC-3MM2. DU-145 and Tsu-Pr1 cells were included for comparative purposes. uPAR expression increases with metastatic passage in these cell lines and accompanies increased growth and motility responses in the presence of uPA. Growth factors TGFβ1 and IGF-1 induce uPAR in all three prostate cancer lines; however, PC-3M and PC-3MM2 cells also respond to bFGF. Of the cell lines tested, PC-3MM2 most uniformly respond to added TGFβ1, IGF-1 and bFGF. These results show that in two progressive derivatives from repeated metastasis of PC-3 cells, constitutive and growth factor-induced uPAR expression is enhanced. This increased uPAR facilitates the properties of growth and motility.
Literatur
1.
2.
Zurück zum Zitat Biliran H, Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61:8676–8682PubMed Biliran H, Sheng S (2001) Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 61:8676–8682PubMed
3.
Zurück zum Zitat Bissell MJ, Le Beyec J, Anderson RL (2002) Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases. J Natl Cancer Inst 94:4–5 Bissell MJ, Le Beyec J, Anderson RL (2002) Prostate cancer in bone: importance of context for inhibition of matrix metalloproteinases. J Natl Cancer Inst 94:4–5
4.
Zurück zum Zitat Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578-83PubMed Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578-83PubMed
5.
Zurück zum Zitat Delworth MG, Nishioka K, Pettaway CA, Gutman M, Killion JJ, Von Eschenbach AC, Fidler IJ (1995) Systemic administration of 4-amidinoindanon-1-(2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncol 6:293–299 Delworth MG, Nishioka K, Pettaway CA, Gutman M, Killion JJ, Von Eschenbach AC, Fidler IJ (1995) Systemic administration of 4-amidinoindanon-1-(2′-amidino)-hydrazone, a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int J Oncol 6:293–299
6.
Zurück zum Zitat Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA (1997) Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57:3594–3599PubMed Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA (1997) Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res 57:3594–3599PubMed
7.
Zurück zum Zitat Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16:513–528CrossRefPubMed Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998) Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis 16:513–528CrossRefPubMed
8.
Zurück zum Zitat Greene GF, Kitadal Y, Pettaway CA, Von Eschenbach AC, Bucana CD, Fidler IJ (1997) Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150:1571–1582PubMed Greene GF, Kitadal Y, Pettaway CA, Von Eschenbach AC, Bucana CD, Fidler IJ (1997) Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150:1571–1582PubMed
9.
Zurück zum Zitat Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan ES, Boyd D (1992) Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombo Haemost 68:662–666 Hollas W, Hoosein N, Chung LWK, Mazar A, Henkin J, Kariko K, Barnathan ES, Boyd D (1992) Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thrombo Haemost 68:662–666
10.
Zurück zum Zitat Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420:79–85CrossRefPubMed Hoyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420:79–85CrossRefPubMed
11.
Zurück zum Zitat Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39:123–129CrossRefPubMed Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999) Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 39:123–129CrossRefPubMed
12.
Zurück zum Zitat Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627–1636PubMed Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627–1636PubMed
13.
Zurück zum Zitat Rabbani SA, Gladu J (2002) Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62:2390–23970 Rabbani SA, Gladu J (2002) Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 62:2390–23970
14.
Zurück zum Zitat Rabbani SA, Xing RH (1998) Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12:911–2PubMed Rabbani SA, Xing RH (1998) Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int J Oncol 12:911–2PubMed
15.
Zurück zum Zitat Sehgal I, Forbes K, Webb M (2003) Reduced expression of MMPs, plasminogen activators and TIMPS in prostate cancer cells during repeated metastatic selection. Anticancer Res 23: (in press) Sehgal I, Forbes K, Webb M (2003) Reduced expression of MMPs, plasminogen activators and TIMPS in prostate cancer cells during repeated metastatic selection. Anticancer Res 23: (in press)
16.
Zurück zum Zitat Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, Von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577–81PubMed Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, Von Eschenbach AC, Chung LW (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577–81PubMed
17.
Zurück zum Zitat Thompson TC, Timme TL, Sehgal I (1998) Oncogenes, growth factors, and hormones in prostate cancer. In: Dickson RB, Salomon DS (eds) Hormones and growth factors in development and neoplasia. Wiley-Liss, New York, pp 327–359 Thompson TC, Timme TL, Sehgal I (1998) Oncogenes, growth factors, and hormones in prostate cancer. In: Dickson RB, Salomon DS (eds) Hormones and growth factors in development and neoplasia. Wiley-Liss, New York, pp 327–359
18.
Zurück zum Zitat Varkarakis MJ, Winterberger AR, Gaeta J, Moore RH, Murphy GP (1974) Lung metastases in prostate carcinoma. Urology 3:447–452PubMed Varkarakis MJ, Winterberger AR, Gaeta J, Moore RH, Murphy GP (1974) Lung metastases in prostate carcinoma. Urology 3:447–452PubMed
19.
Zurück zum Zitat Von Bokhoven A, Garcia MV, Korch C, Miller, GJ (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res61:6340–6344 Von Bokhoven A, Garcia MV, Korch C, Miller, GJ (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res61:6340–6344
20.
Zurück zum Zitat Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349PubMed Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF (2000) The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60:342-349PubMed
Metadaten
Titel
Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis
verfasst von
Katie Forbes
Karin Gillette
Laura A. Kelley
Inder Sehgal
Publikationsdatum
01.04.2004
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 1/2004
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-003-0395-3

Weitere Artikel der Ausgabe 1/2004

World Journal of Urology 1/2004 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.